Skip to content

iUni G2+ Prospective Study

A Prospective, Multi-Center Study to Evaluate the ConforMIS iUni® G2+ Unicompartmental Knee Resurfacing Device

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01820676
Enrollment
28
Registered
2013-03-29
Start date
2013-07-15
Completion date
2022-10-14
Last updated
2023-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Brief summary

This study is designed to monitor long term clinical outcomes of the iUni G2+ unicompartmental knee replacement

Detailed description

The study subjects will be followed for 10 years post implant. The follow-up visit schedule will include visits at 6 weeks, 6 months, 1 year, 2 years, 5 years and 10 years post implant.

Interventions

DEVICEiUni G2+

The iUni G2+ Unicompartmental Resurfacing Device (iUni) is an FDA cleared and CE Marked implant designed for patients with damage isolated to either the medial or lateral tibiofemoral compartment of the knee. The patient-specific iUni is designed from a CT scan of an individual patient's knee using a design process which interactively maps the diseased area and defines the extent of misalignment present in the knee. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation (Fitz).

Sponsors

Restor3D
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Clinical condition included in the approved Indications For Use * Unicompartmental osteoarthritis of the medial or lateral tibiofemoral compartment * Willingness to participate in the clinical study, to give informed consent, and to attend all follow-up visits * \> 18 years of age

Exclusion criteria

* Simultaneous bilateral procedure required * BMI \> 35 * Treatment for cancer within the past 5 years, with the exception of skin cancer * Poorly controlled diabetes * Neuromuscular conditions which prevent patient from participating in study activities * Active local or systemic infection * Immunocompromised * Fibromyalgia or other general body pain related condition * Advanced tricompartmental osteoarthritis * Symptomatic patellofemoral disease * Rheumatoid arthritis or other forms of inflammatory joint disease (excluding Gout unless it is in the treated knee or limiting overall function) * Loss of bone or musculature, osteoporosis, osteonecrosis, neuromuscular or vascular compromise in the area of the joint to be operated to an extent that the procedure is unjustified. Osteoporosis is defined by more than -2.5 standard deviations from the T score as measured on a Dual Energy X-Ray Absortiometry Scan (DEXA) within 2 years of surgery. * Advanced loss of osteochondral structure on the affected femoral condyle * Compromised ACL, PCL or collateral ligament * Severe (\>15º) fixed valgus or varus deformity * Extension deficit \> 15 º * Prior history of failed implant surgery of the joint to be treated * Unwilling or unable to comply with study requirements * Participation in another clinical study which would confound results

Design outcomes

Primary

MeasureTime frame
2011 Knee Society Score1 Year
KOOS Score1 Year
Oxford Knee Score1 Year

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026